This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. Kai He is an innovative medical oncologist who specializes in the care of lung cancer and malignant pleural mesothelioma patients at the James Cancer Hospital of The Ohio State University. Dr. He’s expertise lies in providing personalized care based on his patients’ unique clinical, genetic, and immunological characteristics.
Dr. He is also a physician-scientist within Ohio State University Comprehensive Cancer Center’s Translational Therapeutics Program, where he focuses on cancer epigenetics, genomics and immunology, and their associated novel biomarker and therapeutic development in treating lung cancer and other thoracic malignancies.
Education and Career
Dr. He attended medical school at the Peking Union Medical College in Beijing and continued there for his internship in Internal Medicine. He followed this stage in his education by earning a Ph.D. in Cell Biology at the University of Alabama at Birmingham, then went on to an internship in Internal Medicine and Residency at the North Shore Long Island Jewish. Dr. He finished his education by completing clinical and research fellowships in Medical Oncology at Johns Hopkins Hospital, where he was awarded a T32 training grant for studying epigenetics and cancer immunity in lung cancer.
Dr. He remained at Johns Hopkins as a member of the Medical Oncology faculty at the Sidney Kimmel Comprehensive Cancer Center and the Johns Hopkins School of Medicine, then joined the faculty at Ohio State University’s Wexner School of Medicine and began practicing as part of the thoracic oncology program at James Cancer Hospital.
Dr. He’s laboratory studies the determinants for the response and resistance to immunotherapy in lung cancer, from the genomic instability and tumor mutation-related neoantigen to the dynamic immune landscape evolution related to immunotherapy. He has co-authored over 30 articles published in peer-reviewed journals, including Cancer Discovery, Journal of Thoracic Oncology, Clinical Lung Cancer, and Journal of Hematology & Oncology. He also serves as an ad hoc reviewer for many journals and is a member of the Pelotonia Institute for Immuno-Oncology and the James Cancer Center Clinical Scientific Review Committee.Get Your FREE Mesothelioma Packet
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.